1. Home
  2. KWR vs SRPT Comparison

KWR vs SRPT Comparison

Compare KWR & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quaker Houghton

KWR

Quaker Houghton

HOLD

Current Price

$144.46

Market Cap

2.3B

Sector

Industrials

ML Signal

HOLD

Logo Sarepta Therapeutics Inc. (DE)

SRPT

Sarepta Therapeutics Inc. (DE)

HOLD

Current Price

$15.31

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KWR
SRPT
Founded
1918
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.5B
IPO Year
1994
2000

Fundamental Metrics

Financial Performance
Metric
KWR
SRPT
Price
$144.46
$15.31
Analyst Decision
Strong Buy
Hold
Analyst Count
3
29
Target Price
$167.00
$25.85
AVG Volume (30 Days)
119.0K
2.6M
Earning Date
04-30-2026
05-06-2026
Dividend Yield
1.52%
N/A
EPS Growth
N/A
N/A
EPS
1.13
2.88
Revenue
$1,888,634,000.00
$2,198,237,000.00
Revenue This Year
$5.16
N/A
Revenue Next Year
$3.63
N/A
P/E Ratio
$126.96
$5.21
Revenue Growth
2.66
15.58
52 Week Low
$111.42
$10.42
52 Week High
$183.01
$25.32

Technical Indicators

Market Signals
Indicator
KWR
SRPT
Relative Strength Index (RSI) 55.06 34.08
Support Level $128.25 N/A
Resistance Level $145.30 $23.54
Average True Range (ATR) 4.92 0.73
MACD -0.25 -0.06
Stochastic Oscillator 64.85 15.56

Price Performance

Historical Comparison
KWR
SRPT

About KWR Quaker Houghton

Quaker Houghton manufactures and sells a variety of industrial process fluids. The company's product portfolio includes metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die-cast mold releases, heat treatment and quenchants, metal forging fluids, hydraulic fluids, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, rod and wire drawing fluids, and surface treatment chemicals. The company's geographic segments include the Americas, EMEA, and Asia/Pacific. The majority of the company's revenue is earned from the Americas.

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.

Share on Social Networks: